3 min read 3 Aug 22
For more information on the financial terms used in this article, please consult the glossary.
Horiba is a Japanese manufacturer of state-of-the-art measurement equipment and analytical devices, used across a wide range of medical, environmental and automotive applications.
Horiba’s largest business segment is automotive, where its vehicle emission measurement systems have been adopted as the primary standard by many national certification bodies. In 2021, the company announced its vehicle electrification offering, which serves all relevant stages of research, development, validation, certification and end-of line verification. It covers all varieties of e-power trains, including those with batteries, fuel cells and hybrid architecture. The total solution ranges from single component testing to turnkey testing solutions, and includes consulting and other services throughout the whole vehicle development process.
As countries across the world push towards their net-zero emissions goals and enact policies to phase out internal combustion vehicles, Horiba should play a crucial role in enabling electric vehicle adoption, in our view.
Horiba also makes a positive impact in the medical sector, by manufacturing blood testing instruments and chemical reagents for diagnostics. It was the first company in the world to develop a Hematology and CRP Analyser, which simultaneously measures both red blood cells and inflammation, helping to facilitate faster and more accurate diagnosis of medical issues.
The company also produces water quality and air pollution measurement systems for a variety of industries, helping to ensure public safety, security and health.
All company data sourced from Horiba. Figures shown were latest available from company literature, as at July 2022.
This information is not an offer or solicitation of an offer for the purchase of shares in any of M&G’s funds.
Before subscribing you should read the Prospectus and the Key Investor Information Document.
This financial promotion is issued by M&G Luxembourg S.A. Registered Office: 16, boulevard Royal, L-2449, Luxembourg. The Portuguese Securities Market Commission (Comissão do Mercado de Valores Mobiliários, the “CMVM”) has received a passporting notification under Directive 2009/65/EC of the European Parliament and of the Council and the Commission Regulation (EU) 584/2010 enabling the fund to be distributed to the public in Portugal.
The views expressed here should not be taken as a recommendation, advice or forecast.
The value and income from any fund's assets will go down as well as up. This will cause the value of your investment to fall as well as rise. There is no guarantee that any fund will achieve its objective and you may get back less than you originally invested.